Dian Kang

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies

Zhihui Kuang, Min Wu, Zhihai Wu, 2022, Cancer Immunology, Immunotherapy.

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies

Zhihui Kuang, Min Wu, Zhihai Wu, 2022, Cancer Immunology, Immunotherapy.

Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305

Chuan-fei Yu, Lan Wang, M. H. Xie, 2023, Antibody Therapeutics.